The upgrade is based on Moody's expectation of robust earnings growth for Eli Lilly in the coming years. This growth is ...

Children who inherit genetic mutations from parents with early-onset Alzheimer’s typically show signs of dementia at the same ...

The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...

Weight loss drugs are huge these days, and Eli Lilly (LLY) is leading the pack when it comes to these. However, today’s ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Eli Lilly and Co (NYSE:LLY) stock is trading higher after the company released better-than-expected fourth-quarter earnings ...

An international clinical trial aimed at preventing Alzheimer’s disease (AD) in young adults who are at risk of developing ...

Eli Lilly and Company LLY reported fourth-quarter 2024 adjusted earnings per share (“EPS”) of $5.32, which beat the Zacks Consensus Estimate of $5.03 per share. Earnings rose 114% year over year.

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...

The Washington University trial comes as part of a larger platform study which hopes to understand if Alzheimer's disease can ...

While reporting financial results for the fourth quarter on Thursday, drugmaker Eli Lilly and Co. (LLY) initiated its earnings, ...